AR068536A1 - Vacuna antigripal inactivada - Google Patents
Vacuna antigripal inactivadaInfo
- Publication number
- AR068536A1 AR068536A1 ARP080104130A ARP080104130A AR068536A1 AR 068536 A1 AR068536 A1 AR 068536A1 AR P080104130 A ARP080104130 A AR P080104130A AR P080104130 A ARP080104130 A AR P080104130A AR 068536 A1 AR068536 A1 AR 068536A1
- Authority
- AR
- Argentina
- Prior art keywords
- inactivated
- vaccine
- influenza
- virus
- influenza virus
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 229960003971 influenza vaccine Drugs 0.000 abstract 3
- 241000712461 unidentified influenza virus Species 0.000 abstract 3
- 239000002671 adjuvant Substances 0.000 abstract 2
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 abstract 2
- 238000004113 cell culture Methods 0.000 abstract 2
- 150000002016 disaccharides Chemical class 0.000 abstract 2
- 150000002772 monosaccharides Chemical class 0.000 abstract 2
- 229960000380 propiolactone Drugs 0.000 abstract 2
- 241000271566 Aves Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente se refiere a vacunas antigripales inactivadas y con adyuvantes. La presente brinda una vacuna que supera muchas de las desventajas de las vacunas antigripales inactivadas existentes. La presente brinda una vacuna antigripal inactivada, que comprende el virus de la influenza entero inactivado con beta propiolactona (BPL) y que comprende, como adyuvante, uno o más derivados de monosacáridos o disacáridos que tienen al menos uno pero no más de N-1 grupos éster de ácido graso y, opcionalmente, uno pero no más de N-1 grupos éster de sulfato, donde N es el numero de grupos hidroxilo del monosacárido o disacárido del cual se obtiene el derivado. El virus de la influenza en una vacuna de acuerdo con la presente se obtiene, preferentemente, de un cultivo celular. Los métodos para producir el virus de la influenza en un cultivo celular son conocidos en el arte. El virus se puede cultivar en células de origen mamífero, aviar; o humano, tales como células Madin Darby Canine Kidney (MDCK), Vero, MDBK, CLDK, EBx o PerC6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97456807P | 2007-09-24 | 2007-09-24 | |
| EP07117050 | 2007-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068536A1 true AR068536A1 (es) | 2009-11-18 |
Family
ID=39590199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104130A AR068536A1 (es) | 2007-09-24 | 2008-09-24 | Vacuna antigripal inactivada |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2195020A1 (es) |
| CN (1) | CN101808659A (es) |
| AR (1) | AR068536A1 (es) |
| BR (1) | BRPI0817230A2 (es) |
| TW (1) | TW200927928A (es) |
| WO (1) | WO2009040343A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9278999B2 (en) | 2012-01-27 | 2016-03-08 | Newport Laboratories | Influenza C virus and vaccine |
| CA2954740C (en) | 2014-07-11 | 2022-10-18 | National Research Council Of Canada | Sulfated-glycolipids as adjuvants for vaccines |
| CN104792985A (zh) * | 2015-04-21 | 2015-07-22 | 乾元浩生物股份有限公司 | 定性定量分析禽用禽流感病毒抗原有效成分的方法 |
| CA3083576A1 (en) * | 2017-09-07 | 2019-03-14 | Hawaii Biotech, Inc. | Filovirus vaccine and methods of use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1104767A1 (en) * | 1999-11-30 | 2001-06-06 | Stichting Dienst Landbouwkundig Onderzoek | Mono- and disaccharide derivatives containing both fatty acid ester and sulfate ester groups |
| US20090304742A1 (en) * | 2005-11-04 | 2009-12-10 | Novartis Vaccines And Diagnostics Srl | Influenza vaccines with reduced amount of emulsion adjuvant |
-
2008
- 2008-09-19 TW TW097136110A patent/TW200927928A/zh unknown
- 2008-09-23 CN CN200880108502A patent/CN101808659A/zh active Pending
- 2008-09-23 BR BRPI0817230A patent/BRPI0817230A2/pt not_active IP Right Cessation
- 2008-09-23 EP EP08804610A patent/EP2195020A1/en not_active Withdrawn
- 2008-09-23 WO PCT/EP2008/062694 patent/WO2009040343A1/en not_active Ceased
- 2008-09-24 AR ARP080104130A patent/AR068536A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200927928A (en) | 2009-07-01 |
| CN101808659A (zh) | 2010-08-18 |
| WO2009040343A1 (en) | 2009-04-02 |
| EP2195020A1 (en) | 2010-06-16 |
| BRPI0817230A2 (pt) | 2017-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013022397A2 (pt) | vacinas combinadas com doses menores de antígeno e/ou adjuvante | |
| MX2020003995A (es) | Nuevas moleculas de acido nucleico artificiales. | |
| BR112018012873A2 (pt) | vacina de vírus zika | |
| BR112013029834A2 (pt) | vacinas individualizadas para câncer | |
| BR112018008090A2 (pt) | vacina de vírus do herpes simplex. | |
| BR112012004698A2 (pt) | métodos de redução de atividade virucida em composições de pcv-2 e composições de pcv-2 com uma imonugenicidade aprimorada. | |
| BR112018008078A2 (pt) | vacina de vírus influenza de amplo espectro | |
| BR112012020839A2 (pt) | vacinas para uso na profilaxe e tratamento de doença de vírus da influenza | |
| MX2017014127A (es) | Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos. | |
| AR073959A1 (es) | Vacuna de combinacion con tos ferina acelular y metodo para su elaboracion | |
| EA201890942A1 (ru) | Мультивалентные вакцины с синтетическими наноносителями | |
| BR112015018270A2 (pt) | composições que compreendem 15-ohepa e métodos de uso das mesmas | |
| UY33297A (es) | Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas | |
| BR112019009131A2 (pt) | vacina contra o parvovírus suíno, o vírus da síndrome respiratória e reprodutiva dos suínos e métodos de produção das mesmas | |
| BR112018010503A2 (pt) | ovo de ave, método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, ave transgênica, e método para produzir uma ave | |
| BR112015005056A2 (pt) | vacinas de combinação com sorogrupo b meningococcus e d/t/p | |
| PE20151588A1 (es) | Vacuna contra el virus del dengue | |
| BR112015000585A8 (pt) | método para preparar uma cepa mutante de mycoplasma hyopneumoniae, vetores, cepa mutante, vacina, kit de vacinação e usos do vetor e da cepa mutante | |
| MX373361B (es) | Composiciones inmunológicas que contienen histophilus somni atenuado. | |
| AR068419A1 (es) | Cepas de mycoplasma atenuadas vivas | |
| AR068536A1 (es) | Vacuna antigripal inactivada | |
| CO2017007057A2 (es) | Vacuna contra la fiebre aftosa | |
| CU20180025A7 (es) | Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue | |
| BR112012030659B8 (pt) | Parvovírus vivo atenuado, vacinas que o compreendem e método para a fabricação das referidas vacinas | |
| BR112016030294A8 (pt) | cepa de bactérias probióticas de lactobacillus e uma vacina de aves domésticas, composição, ovo de aves domésticas embrionado, kit, e, método de vacinação in ovo de aves domésticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |